Trial Profile

An Open-Label Multi-Center Phase Ib/II Study of Anti-PD-1/CTLA-4 Bispecific Antibody AK104 in Combination With Lenvatinib As the First-Line Therapy for Patients With Advanced Hepatocellular Carcinoma

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 30 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cadonilimab (Primary) ; Lenvatinib (Primary)
Indications Liver cancer
Focus Therapeutic Use
Sponsors Akeso Biopharma

Most Recent Events

23 Apr 2024 Status changed from recruiting to completed.
24 Oct 2023 Results (n=31 , cut off : July 28,2023 ) presented at the 48th European Society for Medical Oncology Congress.
24 Oct 2023 According to an Akeso Biopharma Media Release, data from this study were presented at the 2023 European Society for Medical Oncology (ESMO) Congress.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com